$SPRO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Spero Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Spero Therapeutics, Inc.. Get notifications about new insider transactions in Spero Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 10 2021 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 21.74 | 3,000 | 65,215 | 3,829,209 | 3.8 M to 3.8 M (-0.08 %) |
Feb 04 2021 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 18.99 | 34,144 | 648,255 | 3,832,209 | 3.9 M to 3.8 M (-0.88 %) |
Feb 04 2021 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 18.98 | 29,354 | 557,101 | 3,866,353 | 3.9 M to 3.9 M (-0.75 %) |
Feb 04 2021 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 18.99 | 22,841 | 433,771 | 3,895,707 | 3.9 M to 3.9 M (-0.58 %) |
Feb 04 2021 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 19.24 | 13,661 | 262,861 | 3,918,548 | 3.9 M to 3.9 M (-0.35 %) |
Feb 03 2021 | SPRO | Spero Therapeutics ... | Keutzer Timothy | Chief Development O ... | Option Exercise | A | 19.18 | 57,432 | 1,101,546 | 57,432 | |
Feb 03 2021 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Option Exercise | A | 19.18 | 57,432 | 1,101,546 | 57,432 | |
Feb 03 2021 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Option Exercise | A | 19.18 | 179,319 | 3,439,338 | 179,319 | |
Feb 03 2021 | SPRO | Spero Therapeutics ... | Melnick David A. | Chief Medical Offic ... | Option Exercise | A | 19.18 | 57,432 | 1,101,546 | 57,432 | |
Jan 06 2021 | SPRO | Spero Therapeutics ... | Smith Cynthia | Director | Option Exercise | A | 17.93 | 2,629 | 47,138 | 2,629 | |
Jan 06 2021 | SPRO | Spero Therapeutics ... | THOMAS FRANK E | Director | Option Exercise | A | 17.93 | 1,314 | 23,560 | 1,314 | |
Jan 06 2021 | SPRO | Spero Therapeutics ... | Deshpande Milind | Director | Option Exercise | A | 17.93 | 2,629 | 47,138 | 2,629 | |
Dec 18 2020 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 18.81 | 250,000 | 4,703,225 | 3,932,209 | 4.2 M to 3.9 M (-5.98 %) |
Dec 18 2020 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 18.62 | 14,933 | 278,035 | 4,182,209 | 4.2 M to 4.2 M (-0.36 %) |
Nov 10 2020 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 13.77 | 125,900 | 1,734,071 | 4,197,142 | 4.3 M to 4.2 M (-2.91 %) |
Nov 06 2020 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 13.77 | 5,000 | 68,874 | 4,323,042 | 4.3 M to 4.3 M (-0.12 %) |
Nov 06 2020 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 13.98 | 96,600 | 1,350,333 | 4,328,042 | 4.4 M to 4.3 M (-2.18 %) |
Nov 06 2020 | SPRO | Spero Therapeutics ... | Aquilo Capital Management, LLC | 10% Owner | Sell | S | 14.26 | 72,500 | 1,033,741 | 4,424,642 | 4.5 M to 4.4 M (-1.61 %) |
Nov 05 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 7,370 | 43,483 | 494,809 | |
Nov 05 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 2,137 | 12,608 | 502,179 | |
Nov 05 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.43 | 7,370 | 106,335 | 65,817 | 73.2 K to 65.8 K (-10.07 %) |
Nov 05 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 7,370 | 43,483 | 73,187 | 65.8 K to 73.2 K (+11.20 %) |
Nov 05 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.27 | 2,137 | 30,490 | 65,817 | 68 K to 65.8 K (-3.14 %) |
Nov 05 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 2,137 | 12,608 | 67,954 | 65.8 K to 68 K (+3.25 %) |
Oct 27 2020 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 13.52 | 7,500 | 101,400 | 7,500 | |
Oct 27 2020 | SPRO | Spero Therapeutics ... | THOMAS FRANK E | Director | Option Exercise | A | 13.52 | 7,500 | 101,400 | 7,500 | |
Oct 27 2020 | SPRO | Spero Therapeutics ... | Smith Cynthia | Director | Option Exercise | A | 13.52 | 7,500 | 101,400 | 7,500 | |
Oct 27 2020 | SPRO | Spero Therapeutics ... | Jackson Scott Thomas | Director | Option Exercise | A | 13.52 | 7,500 | 101,400 | 7,500 | |
Oct 27 2020 | SPRO | Spero Therapeutics ... | Deshpande Milind | Director | Option Exercise | A | 13.52 | 7,500 | 101,400 | 7,500 | |
Oct 27 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 20 | 118 | 504,316 | |
Oct 27 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.25 | 20 | 285 | 65,817 | 65.8 K to 65.8 K (-0.03 %) |
Oct 27 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 20 | 118 | 65,837 | 65.8 K to 65.8 K (+0.03 %) |
Oct 27 2020 | SPRO | Spero Therapeutics ... | VINK PATRICK V.J.J. | Director | Option Exercise | A | 13.52 | 7,500 | 101,400 | 7,500 | |
Oct 27 2020 | SPRO | Spero Therapeutics ... | Pottage John C Jr | Director | Option Exercise | A | 13.52 | 7,500 | 101,400 | 7,500 | |
Sep 10 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 774 | 4,567 | 518,808 | |
Sep 10 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.25 | 774 | 11,030 | 65,817 | 66.6 K to 65.8 K (-1.16 %) |
Sep 10 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 774 | 4,567 | 66,591 | 65.8 K to 66.6 K (+1.18 %) |
Sep 10 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 774 | 4,567 | 518,808 | |
Sep 10 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.25 | 774 | 11,030 | 65,817 | 66.6 K to 65.8 K (-1.16 %) |
Sep 10 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 774 | 4,567 | 66,591 | 65.8 K to 66.6 K (+1.18 %) |
Jul 09 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 2,293 | 13,529 | 519,582 | |
Jul 09 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 754 | 4,449 | 521,875 | |
Jul 09 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.31 | 2,293 | 32,807 | 65,817 | 68.1 K to 65.8 K (-3.37 %) |
Jul 09 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 2,293 | 13,529 | 68,110 | 65.8 K to 68.1 K (+3.48 %) |
Jul 09 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.25 | 754 | 10,745 | 65,817 | 66.6 K to 65.8 K (-1.13 %) |
Jul 09 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 754 | 4,449 | 66,571 | 65.8 K to 66.6 K (+1.15 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 2,642 | 15,588 | 522,629 | |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 3,880 | 22,892 | 525,271 | |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 8,045 | 47,466 | 529,151 | |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | M | 5.90 | 2,613 | 15,417 | 537,196 | |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.25 | 2,642 | 37,650 | 65,817 | 68.5 K to 65.8 K (-3.86 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 2,642 | 15,588 | 68,459 | 65.8 K to 68.5 K (+4.01 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.28 | 3,880 | 55,420 | 65,817 | 69.7 K to 65.8 K (-5.57 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 3,880 | 22,892 | 69,697 | 65.8 K to 69.7 K (+5.90 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.33 | 8,045 | 115,264 | 65,817 | 73.9 K to 65.8 K (-10.89 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 8,045 | 47,466 | 73,862 | 65.8 K to 73.9 K (+12.22 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Sell | S | 14.30 | 2,613 | 37,365 | 65,817 | 68.4 K to 65.8 K (-3.82 %) |
Jun 29 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Buy | M | 5.90 | 2,613 | 15,417 | 68,430 | 65.8 K to 68.4 K (+3.97 %) |
Jun 23 2020 | SPRO | Spero Therapeutics ... | Jackson Scott Thomas | Director | Option Exercise | A | 13.94 | 15,000 | 209,100 | 15,000 | |
Feb 03 2020 | SPRO | Spero Therapeutics ... | Melnick David A. | Chief Medical Offic ... | Option Exercise | A | 9.34 | 55,000 | 513,700 | 55,000 | |
Feb 03 2020 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | A | 9.34 | 180,000 | 1,681,200 | 180,000 | |
Feb 03 2020 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Option Exercise | A | 9.34 | 55,000 | 513,700 | 55,000 | |
Feb 03 2020 | SPRO | Spero Therapeutics ... | Keutzer Timothy | Chief Development O ... | Option Exercise | A | 9.34 | 55,000 | 513,700 | 55,000 | |
Jan 06 2020 | SPRO | Spero Therapeutics ... | THOMAS FRANK E | Director | Option Exercise | A | 9.87 | 2,704 | 26,688 | 2,704 | |
Jan 06 2020 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 9.87 | 5,408 | 53,377 | 5,408 | |
Jan 06 2020 | SPRO | Spero Therapeutics ... | VINK PATRICK V.J.J. | Director | Option Exercise | A | 9.87 | 5,408 | 53,377 | 5,408 | |
Jan 06 2020 | SPRO | Spero Therapeutics ... | Deshpande Milind | Director | Option Exercise | A | 9.87 | 5,408 | 53,377 | 5,408 | |
Jun 05 2019 | SPRO | Spero Therapeutics ... | Smith Cynthia | Director | Option Exercise | A | 10.67 | 6,073 | 64,799 | 6,073 | |
Jun 05 2019 | SPRO | Spero Therapeutics ... | Pottage John C Jr | Director | Option Exercise | A | 10.67 | 6,073 | 64,799 | 6,073 | |
Jun 05 2019 | SPRO | Spero Therapeutics ... | THOMAS FRANK E | Director | Option Exercise | A | 10.67 | 6,073 | 64,799 | 6,073 | |
Jun 05 2019 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 10.67 | 6,073 | 64,799 | 6,073 | |
Jun 05 2019 | SPRO | Spero Therapeutics ... | Deshpande Milind | Director | Option Exercise | A | 10.67 | 6,073 | 64,799 | 6,073 | |
Jun 05 2019 | SPRO | Spero Therapeutics ... | VINK PATRICK V.J.J. | Director | Option Exercise | A | 10.67 | 6,073 | 64,799 | 6,073 | |
Mar 29 2019 | SPRO | Spero Therapeutics ... | Smith Cynthia | Director | Option Exercise | A | 12.81 | 12,146 | 155,590 | 12,146 | |
Jan 02 2019 | SPRO | Spero Therapeutics ... | Parr Thomas R JR | Chief Scientific Of ... | Option Exercise | A | 6.26 | 35,000 | 219,100 | 35,000 | |
Jan 02 2019 | SPRO | Spero Therapeutics ... | Melnick David A. | Chief Medical Offic ... | Option Exercise | A | 6.26 | 65,000 | 406,900 | 65,000 | |
Jan 02 2019 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Option Exercise | A | 6.26 | 65,000 | 406,900 | 65,000 | |
Jan 02 2019 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Option Exercise | A | 6.26 | 65,000 | 406,900 | 65,000 | |
Jan 02 2019 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | CEO and President | Option Exercise | A | 6.26 | 180,000 | 1,126,800 | 180,000 | |
Sep 21 2018 | SPRO | Spero Therapeutics ... | Pottage John C Jr | Director | Option Exercise | A | 10.25 | 12,146 | 124,497 | 12,146 | |
Jul 17 2018 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | P | 12.50 | 80,000 | 1,000,000 | 1,934,006 | 1.9 M to 1.9 M (+4.31 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Option Exercise | M | 5.90 | 4,000 | 23,600 | 20,434 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Sell | S | 17.50 | 4,000 | 70,000 | 1,500 | 5.5 K to 1.5 K (-72.73 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Buy | M | 5.90 | 4,000 | 23,600 | 5,500 | 1.5 K to 5.5 K (+266.67 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Option Exercise | M | 5.90 | 2,000 | 11,800 | 165,833 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Sell | S | 17.50 | 2,000 | 35,000 | 15,181 | 17.2 K to 15.2 K (-11.64 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Buy | M | 5.90 | 2,000 | 11,800 | 17,181 | 15.2 K to 17.2 K (+13.17 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Option Exercise | M | 5.90 | 1,600 | 9,440 | 118,888 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Option Exercise | M | 5.90 | 3,076 | 18,148 | 120,488 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.92 | 200 | 3,584 | 65,817 | 66 K to 65.8 K (-0.30 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.90 | 200 | 3,580 | 66,017 | 66.2 K to 66 K (-0.30 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.71 | 100 | 1,771 | 66,217 | 66.3 K to 66.2 K (-0.15 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.62 | 100 | 1,762 | 66,317 | 66.4 K to 66.3 K (-0.15 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.58 | 400 | 7,032 | 66,417 | 66.8 K to 66.4 K (-0.60 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.55 | 100 | 1,755 | 66,817 | 66.9 K to 66.8 K (-0.15 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.50 | 500 | 8,750 | 66,917 | 67.4 K to 66.9 K (-0.74 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Buy | M | 5.90 | 1,600 | 9,440 | 67,417 | 65.8 K to 67.4 K (+2.43 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.62 | 3,076 | 54,204 | 65,817 | 68.9 K to 65.8 K (-4.46 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Buy | M | 5.90 | 3,076 | 18,148 | 68,893 | 65.8 K to 68.9 K (+4.67 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Option Exercise | M | 5.90 | 4,000 | 23,600 | 20,434 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Sell | S | 17.50 | 4,000 | 70,000 | 1,500 | 5.5 K to 1.5 K (-72.73 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Buy | M | 5.90 | 4,000 | 23,600 | 5,500 | 1.5 K to 5.5 K (+266.67 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Option Exercise | M | 5.90 | 2,000 | 11,800 | 165,833 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Sell | S | 17.50 | 2,000 | 35,000 | 15,181 | 17.2 K to 15.2 K (-11.64 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Buy | M | 5.90 | 2,000 | 11,800 | 17,181 | 15.2 K to 17.2 K (+13.17 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Option Exercise | M | 5.90 | 1,600 | 9,440 | 118,888 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Option Exercise | M | 5.90 | 3,076 | 18,148 | 120,488 | |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.92 | 200 | 3,584 | 65,817 | 66 K to 65.8 K (-0.30 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.90 | 200 | 3,580 | 66,017 | 66.2 K to 66 K (-0.30 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.71 | 100 | 1,771 | 66,217 | 66.3 K to 66.2 K (-0.15 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.62 | 100 | 1,762 | 66,317 | 66.4 K to 66.3 K (-0.15 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.58 | 400 | 7,032 | 66,417 | 66.8 K to 66.4 K (-0.60 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.55 | 100 | 1,755 | 66,817 | 66.9 K to 66.8 K (-0.15 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.50 | 500 | 8,750 | 66,917 | 67.4 K to 66.9 K (-0.74 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Buy | M | 5.90 | 1,600 | 9,440 | 67,417 | 65.8 K to 67.4 K (+2.43 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Sell | S | 17.62 | 3,076 | 54,204 | 65,817 | 68.9 K to 65.8 K (-4.46 %) |
Jul 06 2018 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Buy | M | 5.90 | 3,076 | 18,148 | 68,893 | 65.8 K to 68.9 K (+4.67 %) |
Jun 06 2018 | SPRO | Spero Therapeutics ... | THOMAS FRANK E | Director | Option Exercise | A | 11.54 | 6,073 | 70,082 | 6,073 | |
Jun 06 2018 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 11.54 | 6,073 | 70,082 | 6,073 | |
Jun 06 2018 | SPRO | Spero Therapeutics ... | SOUTHWELL DAVID P | Director | Option Exercise | A | 11.54 | 6,073 | 70,082 | 6,073 | |
Jun 06 2018 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Option Exercise | A | 11.54 | 6,073 | 70,082 | 6,073 | |
Jun 06 2018 | SPRO | Spero Therapeutics ... | Deshpande Milind | Director | Option Exercise | A | 11.54 | 6,073 | 70,082 | 6,073 | |
Jun 06 2018 | SPRO | Spero Therapeutics ... | VINK PATRICK V.J.J. | Director | Option Exercise | A | 11.54 | 6,073 | 70,082 | 6,073 | |
Mar 30 2018 | SPRO | Spero Therapeutics ... | SOUTHWELL DAVID P | Director | Option Exercise | A | 14.25 | 12,146 | 173,081 | 12,146 | |
Jan 05 2018 | SPRO | Spero Therapeutics ... | Melnick David A. | Chief Medical Offic ... | Option Exercise | A | 12.14 | 135,000 | 1,638,900 | 135,000 | |
Dec 15 2017 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Option Exercise | A | 11.63 | 62,540 | 727,340 | 62,540 | |
Dec 15 2017 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Option Exercise | A | 11.63 | 27,795 | 323,256 | 27,795 | |
Dec 15 2017 | SPRO | Spero Therapeutics ... | Parr Thomas R JR | Chief Scientific Of ... | Option Exercise | A | 11.63 | 36,134 | 420,238 | 36,134 | |
Dec 15 2017 | SPRO | Spero Therapeutics ... | Mahadevia Ankit | See Remarks | Option Exercise | A | 11.63 | 125,079 | 1,454,669 | 125,079 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 3,683,045 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 1,250,000 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 982,906 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 1,483,784 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | P | 14.00 | 428,571 | 5,999,994 | 1,854,006 | 1.4 M to 1.9 M (+30.07 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 606,024 | 0 | 1,425,435 | 819.4 K to 1.4 M (+73.96 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 328,992 | 0 | 819,411 | 490.4 K to 819.4 K (+67.08 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 246,272 | 0 | 490,419 | 244.1 K to 490.4 K (+100.87 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 244,147 | 0 | 244,147 | 0 to 244.1 K |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 3,662,178 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 3,119,633 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 1,250,000 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 982,906 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 1,492,645 | 0 | 0 | |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | P | 14.00 | 428,571 | 5,999,994 | 2,408,128 | 2 M to 2.4 M (+21.65 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 602,589 | 0 | 1,979,557 | 1.4 M to 2 M (+43.76 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 513,318 | 0 | 1,376,968 | 863.7 K to 1.4 M (+59.44 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 328,992 | 0 | 863,650 | 534.7 K to 863.7 K (+61.53 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 246,272 | 0 | 534,658 | 288.4 K to 534.7 K (+85.40 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 245,605 | 0 | 288,386 | 42.8 K to 288.4 K (+574.10 %) |
Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Option Exercise | C | 0.00 | 3,683,045 | 0 | 0 |